Quoin Pharmaceuticals, Ltd. (QNRX)

0.6700 +0.0025 (+0.37%) As of 09:41AM EDT. Market open.

Quoin Pharmaceuticals, Ltd.

42127 Pleasant Forest Court
Ashburn, VA 20148-7349
United States
703 980 4182
https://quoinpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 4

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Michael Myers Ph.D.	Co-Founder, CEO & Chairman	661.8k	N/A	1962
Ms. Denise Carter	Co-Founder, COO & Director	537.8k	N/A	1969
Mr. Gordon Bruce Dunn J.D.	Chief Financial Officer	523.38k	N/A	1964

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

Corporate governance

Quoin Pharmaceuticals, Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.